Skip to main content

Table 1 Tumor and demographic characteristics of 253 patients with breast carcinoma and diabetes (128 on and 125 not on metformin) and 320 patients with breast carcinoma without diabetes

From: Long-term use of metformin and the molecular subtype in invasive breast carcinoma patients – a retrospective study of clinical and tumor characteristics

Factor Sub-group Patients with breast carcinoma and diabetes without metformin Patients with breast carcinoma and diabetes on metformin Patients with breast carcinoma without diabetes P1 P2
Median age (years)   69 65 60 0.034 0.0001
Median BMI (kg/m 2 )   29.35 30.30 25.80 0.18 0.0001
Median ASA score   2 2 2 0.78 0.0001
Median tumor size (cm)   2.1 2.05 1.8 0.46 0.014
Median number of metastatic lymph nodes   0.5 1 0 0.79 0.78
Age (years) 70 or less 72 96 248 0.003 0.0001
71 or more 53 32 72
BMI (kg/m 2 ) Less than 30 70 58 258 0.122 0.0001
(N = 562) 30 or more 51 63 62   
ASA score (N = 480) 1 3 0 103 0.21 0.0001
2 77 80 119
3 38 38 22
Diet only (N = 253) No 105 128 - - -
Yes 20 0 -
Therapy with sulphonylurea No 78 69 320 - -
Yes 47 59 0
pT tumour stage pT1 57 63 192 0.031 0.0001
pT2 35 45 87
pT3 6 9 20
pT4 27 11 21
T3 or T4 stage pT1 or pT2 93 108 279 0.035 0.003
pT3 or pT4 33 20 41
N stage (N = 572) pN0 63 65 173 0.90 0.78
pN1 or pN2 62 63 146
Number of metastatic lymph nodes (N = 572) 0 63 63 173 0.68 0.75
1–3 32 39 80
4 or more 30 26 66
M stage M0 120 124 313 0.75 0.55
M1 5 4 7
Type of invasive carcinoma Ductal 103 115 274 0.086 0.23
Lobular or other 22 13 46
Molecular subtype of carcinoma (N = 569) Luminal A 104 99 226 0.60 0.01
Luminal B 11 16 35
HER-2 2 1 25
Triple negative 8 11 31
Tumor differentiation (N = 566) Well or moderate 69 73 177 0.67 0.89
Poor 56 75 136
ER status (10% or more) (N = 570) Positive 113 115 258 0.97 0.008
Negative 12 12 60
PR status (10% or more) Positive 96 90 207 0.28 0.049
Negative 29 37 111
ER status (1% or more) (N = 570) Positive 114 116 263 0.87 0.011
Negative 11 12 57
PR status (1% or more) Positive 106 99 218 0.13 0.001
Negative 19 29 102
HER-2 (N = 569) Negative 112 110 257 0.46 0.06
Positive 13 17 60
Triple-negative tumor (N = 569) No 117 116 286 0.49 0.53
Yes 8 11 31
  1. P1: p-value (DM not on metformin vs. DM on metformin).
  2. P2: p-value (DM not on metformin vs. DM on metformin vs. controls).
  3. ER: estrogen receptor status.
  4. PR: progesteron receptor.